Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101.
A novel, highly cardioselective ultra short-acting beta-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in beta-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This beta-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.
Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
S
S
Iguchi
H
H
Iwamura
M
M
Nishizaki
A
A
Hayashi
K
K
Senokuchi
K
K
Kobayashi
K
K
Sakaki
K
K
Hachiya
Y
Y
Ichioka
M
M
Kawamura
D000319:Adrenergic beta-Antagonists / Q000138:chemical synthesis / Q000494:pharmacology*; D000818:Animals; D004285:Dogs; D006168:Guinea Pigs; D006325:Heart Atria / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects*; D066298:In Vitro Techniques; D009025:Morpholines / Q000138:chemical synthesis / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013610:Tachycardia / Q000188:drug therapy; D014132:Trachea / Q000187:drug effects; D014508:Urea / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D009025:Morpholines; C077049:landiolol; D014508:Urea